Viagra Super Active
$ 50,00 – $ 535,00Price range: $ 50,00 through $ 535,00
Vidalista
$ 24,00 – $ 550,00Price range: $ 24,00 through $ 550,00
Victoza
$ 450,00 – $ 850,00Price range: $ 450,00 through $ 850,00
Victoza is a non-insulin injectable medication designed to improve blood sugar control in adults and children aged 10 and older with type 2 diabetes. It works as a GLP-1 receptor agonist, helping the pancreas release the right amount of insulin when blood sugar levels are high. Beyond glucose management, this treatment is clinically proven to reduce the risk of major cardiovascular events, such as heart attack or stroke, in adults with established heart disease. The medication is administered once daily via a pre-filled dosing pen at any time of day, regardless of meal times. By mimicking natural hormones, Victoza effectively slows digestion and prevents the liver from producing excessive sugar to support long-term health.
Active substance: Liraglutide
SKU:
Victoza
Categories: Diabetes, Heart Disease, Weight Loss
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Victoza belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. Prescribed under federal regulatory supervision in the United States, it is authorized as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
As a prescription-only injectable therapy, Victoza is also indicated to reduce the risk of major adverse cardiovascular events–including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke–in adults with type 2 diabetes mellitus and established cardiovascular disease. This overview provides details on its pharmacological characteristics, clinical administration, safety considerations, and storage requirements.
| Parameter | Details |
|---|---|
| Drug name | Victoza |
| Active ingredient (INN) | Liraglutide |
| Therapeutic class | GLP-1 receptor agonist (AHFS 68:20.06) |
| Dosage form | Solution for subcutaneous injection in a pre-filled pen |
| Route of administration | Subcutaneous injection |
| Prescription status | Prescription (Rx) only |
| Primary purpose | Glycemic control and cardiovascular risk reduction in type 2 diabetes |
Pharmacological Profile and Administration
How the drug works
The active ingredient, liraglutide, is an acylated human glucagon-like peptide-1 (GLP-1) receptor agonist that shares 97% amino acid sequence homology with endogenous human GLP-1. It operates by selectively binding to and activating the GLP-1 receptor. This activation stimulates glucose-dependent insulin secretion from pancreatic beta cells while simultaneously suppressing inappropriately elevated glucagon secretion. Additionally, the mechanism involves a slight delay in gastric emptying. Because insulin release is mediated in a glucose-dependent manner, the risk of hypoglycemia is low when used as monotherapy.
Main uses
Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in patients 10 years of age and older with type 2 diabetes. It is also FDA-approved to decrease the risk of serious cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease. It should be noted that weight reduction observed during treatment is considered a secondary effect; weight management is an off-label use for Victoza specifically, as higher dosages of liraglutide are regulated under separate FDA product labeling. Victoza is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
Dosing schedule
Administration is performed subcutaneously once daily into the abdomen, thigh, or upper arm at any time of day, independent of meals. The initial dosage is 0.6 mg daily for one week. This starting dose is intended to reduce gastrointestinal side effects and is non-therapeutic for long-term glycemic control. Following the initial week, the dose is increased to 1.2 mg daily. If additional glycemic control is required, the dosage may be further increased to a maximum of 1.8 mg daily. Injection sites should be rotated daily within the same body region to minimize local skin reactions.
What happens in the body
Following subcutaneous administration, maximum plasma concentrations (Cmax) of liraglutide are attained approximately 8 to 12 hours post-injection. Absolute bioavailability is estimated at approximately 55%. Liraglutide is extensively bound to plasma proteins (>98%). It is metabolized endogenously by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase (NEP) in a manner similar to large proteins, without a specific organ serving as the primary route of elimination. The mean elimination half-life is approximately 13 hours, supporting a once-daily dosing regimen.
Safety Information, Interactions, and FAQ
Important precautions
Victoza carries a Boxed Warning regarding the risk of thyroid C-cell tumors. In rodent studies, liraglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Clinical monitoring should include screening for signs of thyroid neoplasms, such as mass neck lesions, dysphagia, or persistent hoarseness. Additional clinical warnings include acute pancreatitis, acute gallbladder disease, hypoglycemia when co-administered with secretagogues or insulin, and potential renal impairment secondary to dehydration.
Adverse reactions
The most common adverse reactions reported in clinical trials involve the gastrointestinal system. These include nausea, diarrhea, vomiting, decreased appetite, dyspepsia, and constipation. Nausea occurs most frequently during the initial dose-escalation period and tends to lessen over time with continued therapy. Other documented side effects include injection site reactions (such as rash or erythema), headache, and hypoglycemia (predominantly when combined with sulfonylureas or exogenous insulin).
Compatibility with other medicines
Because liraglutide causes a delay in gastric emptying, it has the potential to impact the absorption rate of concomitantly administered oral medications. Caution should be exercised when co-administering oral drugs that require rapid gastrointestinal absorption or those with a narrow therapeutic index. Furthermore, combining Victoza with insulin secretagogues (such as sulfonylureas) or exogenous insulin elevates the risk of hypoglycemia. A dose reduction of the secretagogue or insulin may be required upon initiating treatment.
Red flags
Immediate medical attention is warranted if severe, persistent abdominal pain occurs, which may radiate to the back and indicate acute pancreatitis. Emergency medical care should also be sought if signs of a severe hypersensitivity reaction develop, including facial edema, swelling of the lips or throat, severe skin rash, or dyspnea. Dehydration caused by persistent vomiting or diarrhea can lead to acute kidney injury and requires prompt clinical evaluation.
If you skip a dose
If a dose is missed, the regular once-daily schedule should be resumed with the next scheduled dose. An extra dose should not be administered, nor should the daily dose be doubled. If more than three days have elapsed since the last dose, treatment should be reinitiated at 0.6 mg daily to minimize gastrointestinal adverse effects, followed by re-titration according to medical direction.
What to avoid while taking it
Victoza may be taken with or without food. Excessive alcohol consumption should be avoided, as alcohol can unpredictably affect blood glucose levels and increase the risk of hypoglycemia. Patients are advised to maintain adequate fluid intake to mitigate dehydration risks associated with gastrointestinal side effects such as nausea, vomiting, or diarrhea.
Storage and expiration
Unused pre-filled pens must be stored in a refrigerator between 36°F and 46°F (2°C to 8°C). The product must not be frozen; pens that have been frozen must be discarded. After first use, the pen may be kept at controlled room temperature between 59°F and 86°F (15°C to 30°C) or under refrigeration for up to 30 days. Pens should be protected from excessive heat and direct sunlight. The pen cap must remain in place when not in use, and needles must be removed and safely discarded immediately after each injection.
Common questions
Is Victoza a type of insulin?
No, Victoza is not insulin. It is a GLP-1 receptor agonist that stimulates the pancreas to release its own insulin only when blood glucose levels are elevated.
Does Victoza cause weight loss, and is it approved for weight management?
While weight reduction is frequently observed during treatment, Victoza is FDA-approved specifically for glycemic control and cardiovascular risk reduction in type 2 diabetes. Using Victoza solely for weight loss is considered an off-label use.
What should be done if nausea occurs during the first few weeks?
Nausea is a common side effect during initiation and dose escalation. It generally subsides over time. Consuming smaller meals, avoiding fatty foods, and maintaining fluid intake can help manage symptoms. If nausea is severe or persistent, a healthcare professional should be consulted.
Can Victoza be used during pregnancy or breastfeeding?
Data regarding the use of liraglutide in pregnant women are limited and insufficient to evaluate drug-associated risks of major birth defects or miscarriage. Victoza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consultation with a prescribing physician is required.
How long does it take for blood sugar levels to improve after starting treatment?
Reductions in fasting blood glucose levels may be observed within the first week of treatment. However, full therapeutic evaluation based on hemoglobin A1c reduction typically occurs after several weeks to months of consistent daily administration.
This text is for informational purposes only and does not constitute individual medical advice. In accordance with FDA requirements.
Additional information
| Dosage |
6mg |
|---|---|
| Package |
1 injector ,2 injector |
| Ενεργός Ουσία |
Related products
Abana
$ 89,00 – $ 580,00Price range: $ 89,00 through $ 580,00
Active substance: Abana
More Details
This product has multiple variants. The options may be chosen on the product page
Accupril
$ 68,00 – $ 256,00Price range: $ 68,00 through $ 256,00
Active substance: Hypertension
More Details
This product has multiple variants. The options may be chosen on the product page
Actoplus Met
$ 43,00 – $ 343,00Price range: $ 43,00 through $ 343,00
Active substance: metformin, Pioglitazone
More Details
This product has multiple variants. The options may be chosen on the product page
Aggrenox
$ 50,00 – $ 288,00Price range: $ 50,00 through $ 288,00
Active substance: Dipyridamole
More Details
This product has multiple variants. The options may be chosen on the product page
DDAVP spray
$ 64,00 – $ 412,00Price range: $ 64,00 through $ 412,00
Active substance: Desmopressin acetate
More Details
This product has multiple variants. The options may be chosen on the product page
Glucophage
$ 28,00 – $ 97,00Price range: $ 28,00 through $ 97,00
Active substance: metformin
More Details
This product has multiple variants. The options may be chosen on the product page
Glucophage Trio
$ 96,00 – $ 187,00Price range: $ 96,00 through $ 187,00
More Details
This product has multiple variants. The options may be chosen on the product page
Rybelsus
$ 250,00 – $ 880,00Price range: $ 250,00 through $ 880,00
Active substance: Semaglutide
More Details
This product has multiple variants. The options may be chosen on the product page
